Company research
CRISPR Therapeutics AG
CIK 1674416Updated Sep 24, 2026
SecurityCRSP · NASDAQ · equity
Name history
CRISPR Therapeutics AG · through Sep 22, 2026
CRSP price & chart
Loading TradingView…
NASDAQ:CRSP on TradingView ↗About the company
CRISPR Therapeutics and Vertex established a strategic research collaboration in 2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to address the underlying genetic causes of human disease. CASGEVY is the first approved therapy to emerge from this collaboration. Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis. Vertex is the manufacturer and exclusive license holder of CASGEVY.
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,265,243,000Source | 2,242,034,000Source | 2,229,571,000Source | 2,243,057,000Source |
| Property, Plant and Equipment, NetUSD | 115,851,000Source | 134,093,000Source | 151,945,000Source | 163,634,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 347,559,000Source | 298,257,000Source | 389,477,000Source | 211,885,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 25,000,000Source | 200,000,000Source | 0Source |
| Assets, CurrentUSD | 1,985,671,000Source | 1,937,132,000Source | 1,908,078,000Source | 1,853,026,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,843,000Source | 8,306,000Source | 14,386,000Source | 37,708,000Source |
| Operating Lease, Right-of-Use AssetUSD | 131,724,000Source | 143,461,000Source | 153,993,000Source | 156,921,000Source |
| Other Assets, NoncurrentUSD | 24,368,000Source | 15,829,000Source | 1,975,000Source | 4,640,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 343,430,000Source | 309,954,000Source | 346,768,000Source | 367,578,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 3,087,000Source | 2,698,000Source | 2,497,000Source | 2,441,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,947,551,000Source | -1,365,952,000Source | -999,700,000Source | -846,090,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,821,000Source | 1,840,000Source | 1,913,000Source | -15,647,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,921,813,000Source | 1,932,080,000Source | 1,882,803,000Source | 1,875,479,000Source |
| Additional Paid in Capital, Common StockUSD | 3,861,516,000Source | 3,293,556,000Source | 2,878,155,000Source | 2,734,838,000Source |
| Liabilities and EquityUSD | 2,265,243,000Source | 2,242,034,000Source | 2,229,571,000Source | 2,243,057,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 149,120,000Source | 87,782,000Source | 108,791,000Source | 121,107,000Source |
| Operating Lease, Liability, CurrentUSD | 18,578,000Source | 17,288,000Source | 15,625,000Source | 15,842,000Source |
| Accounts Payable, CurrentUSD | 11,138,000Source | 14,709,000Source | 38,147,000Source | 27,428,000Source |
| Operating Lease, Liability, NoncurrentUSD | 188,168,000Source | 206,405,000Source | 223,007,000Source | 228,179,000Source |
| Other Liabilities, NoncurrentUSD | 6,142,000Source | 3,444,000Source | 958,000Source | 5,969,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 89,407,000Source | 41,072,000Source | 45,335,000Source | 77,682,000Source |
| Deferred Tax Liabilities, NetUSD | 1,130,000Source | 214,000Source | 619,000Source | 1,136,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -581,599,000Source | -366,252,000Source | -153,610,000Source | -650,175,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 19,479,000Source | 19,259,000Source | 19,837,000Source | 24,172,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 72,499,000Source | 86,567,000Source | 81,028,000Source | 97,947,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -25,000,000Source | -175,000,000Source | 200,000,000Source | -305,000Source |
| Deferred Income Tax Expense (Benefit)USD | 915,000Source | -484,000Source | -424,000Source | -1,010,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -345,014,000Source | -142,774,000Source | -260,375,000Source | -495,741,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -31,805,000Source | -280,481,000Source | 374,647,000Source | -258,655,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 914,000Source | 1,901,000Source | 9,470,000Source | 37,188,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 426,026,000Source | 331,984,000Source | 62,664,000Source | 38,592,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 49,302,000Source | -91,292,000Source | 177,009,000Source | -715,884,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 2,985,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 72,499,000Source | 86,567,000Source | 81,028,000Source | 97,947,000Source |
| DepreciationUSD | 19,400,000Source | 19,200,000Source | 19,800,000Source | 24,100,000Source |
| General and Administrative ExpenseUSD | 73,542,000Source | 72,977,000Source | 76,162,000Source | 102,464,000Source |
| Income Tax Expense (Benefit)USD | 3,634,000Source | 3,587,000Source | 2,888,000Source | -325,000Source |
| Investment Income, InterestUSD | — | 104,300,000Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | 4,100,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -581,599,000Source | -366,252,000Source | -153,610,000Source | -650,175,000Source |
| Nonoperating Income (Expense)USD | 86,606,000Source | 103,901,000Source | 71,816,000Source | 22,661,000Source |
| Operating ExpensesUSD | 668,081,000Source | 503,880,000Source | 593,744,000Source | 674,359,000Source |
| Other Nonoperating Income (Expense)USD | 86,606,000Source | 103,901,000Source | 71,816,000Source | 22,661,000Source |
| Proceeds from Issuance of Common StockUSD | 398,090,000Source | 300,695,000Source | 32,721,000Source | 970,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,510,000Source | 37,314,000Source | 371,206,000Source | 1,198,000Source |
| Operating Income (Loss)USD | -664,571,000Source | -466,566,000Source | -222,538,000Source | -673,161,000Source |
| Other Nonoperating Income (Expense)USD | 86,606,000Source | 103,901,000Source | 71,816,000Source | 22,661,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -577,965,000Source | -362,665,000Source | -150,722,000Source | -650,500,000Source |
| Income Tax Expense (Benefit)USD | 3,634,000Source | 3,587,000Source | 2,888,000Source | -325,000Source |
| Net Income (Loss) Attributable to ParentUSD | -581,599,000Source | -366,252,000Source | -153,610,000Source | -650,175,000Source |
| Earnings Per Share, BasicUSD per share | -6.47Source | -4.34Source | -1.94Source | -8.36Source |
| Earnings Per Share, DilutedUSD per share | -6.47Source | -4.34Source | -1.94Source | -8.36Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 89,925,109Source | 84,359,126Source | 79,220,930Source | 77,746,575Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 89,925,109Source | 84,359,126Source | 79,220,930Source | 77,746,575Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 2,719,000Source | 4,071,000Source | 3,312,000Source | 685,000Source |
| General and Administrative ExpenseUSD | 73,542,000Source | 72,977,000Source | 76,162,000Source | 102,464,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 32,527,000Source | 41,232,000Source | 30,357,000Source | 1,321,000Source |
| Investment Income, InterestUSD | — | 104,300,000Source | — | — |
| Nonoperating Income (Expense)USD | 86,606,000Source | 103,901,000Source | 71,816,000Source | 22,661,000Source |
| Operating ExpensesUSD | 668,081,000Source | 503,880,000Source | 593,744,000Source | 674,359,000Source |
| Research and Development ExpenseUSD | 284,806,000Source | 320,653,000Source | 387,332,000Source | 461,645,000Source |
Filing attachments
crsp-ex99_1.htm · 8-K · 2026-08-03
EX-99.1 2 crsp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results ZUG, Switzerland and BOSTON, August 3, 2026 - CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Ph. D., Chairman and Chief Executive Officer of CRISPR Therap…
Read attachment ↗crsp-ex99_1.htm · 8-K · 2026-05-04
EX-99.1 2 crsp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results ZUG, Switzerland and BOSTON, May 4, 2026 - CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflected continued execution across CRISPR Therapeutics’ platform,” said Samarth Kulkarni, Ph. D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We expa…
Read attachment ↗crsp-ex4_1.htm · 8-K · 2026-03-16
EX-4.1 2 crsp-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 CRISPR THERAPEUTICS AG AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 16, 2026 1.7308% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. …
Read attachment ↗crsp-ex99_1.htm · 8-K · 2026-03-11
EX-99.1 2 crsp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering ZUG, Switzerland and BOSTON, March 10, 2026 - CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualif…
Read attachment ↗crsp-ex99_2.htm · 8-K · 2026-03-11
EX-99.2 3 crsp-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering ZUG, Switzerland and BOSTON, March 11, 2026 - CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Secu…
Read attachment ↗crsp-ex99_1.htm · 8-K · 2025-11-10
EX-99.1 2 crsp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results -Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patient…
Read attachment ↗